Cowen Downgrades Alimera Sciences (ALIM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
Alimera Sciences (ALIM) Misses Q1 EPS by 4c
May 4, 2016 5:15 PM EDTAlimera Sciences (NASDAQ: ALIM) reported Q1 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.83 million.
"In the U.S. we were pleased to see a record month for... More
